T
Timothy A. Yap
Researcher at University of Texas MD Anderson Cancer Center
Publications - 225
Citations - 11080
Timothy A. Yap is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 28, co-authored 137 publications receiving 8346 citations. Previous affiliations of Timothy A. Yap include The Royal Marsden NHS Foundation Trust & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Peter C.C. Fong,D. S. Boss,Timothy A. Yap,Andrew Tutt,Peijun Wu,Marja Mergui-Roelvink,Peter S. Mortimer,Helen Swaisland,Alan Lau,Mark J. O'Connor,Alan Ashworth,James Carmichael,Stan B. Kaye,Jan H.M. Schellens,Jan H.M. Schellens,Johann S. de Bono +15 more
TL;DR: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCa2 mutation.
Journal ArticleDOI
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C.C. Fong,Timothy A. Yap,D. S. Boss,Craig P. Carden,Marja Mergui-Roelvink,Charlie Gourley,Jacques De Greve,Jan Lubinski,Susan Shanley,Christina Messiou,Roger A'Hern,Andrew Tutt,Alan Ashworth,John F. Stone,James Carmichael,Jan H.M. Schellens,Johann S. de Bono,Stan B. Kaye +17 more
TL;DR: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity, a significant association between the clinical benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups.
Journal ArticleDOI
Targeting the PI3K pathway in cancer: are we making headway?
TL;DR: Considering that oncogenic activation of the PI3K–AKT–mTOR pathway often occurs alongside pro-tumorigenic aberrations in other signalling networks, rational combinations are also needed to optimize the effectiveness of treatment.
Journal ArticleDOI
State-of-the-art strategies for targeting the DNA damage response in cancer
TL;DR: The authors review the progress made to date with PARP inhibitors, describe the expanding landscape of novel anticancer therapies targeting the DNA damage response and potential predictive biomarkers, mechanisms of resistance and combinatorial strategies are discussed.
Journal ArticleDOI
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap,Li Yan,Amita Patnaik,Ivy Fearen,David Olmos,Kyriakos P. Papadopoulos,Richard D. Baird,Liliana Delgado,Adekemi Taylor,Lisa Lupinacci,Ruth Riisnaes,Lorna Pope,Simon P. Heaton,George Thomas,Michelle D. Garrett,Daniel M. Sullivan,Johann S. de Bono,Anthony W. Tolcher +17 more
TL;DR: MK-2206 was well tolerated, with evidence of AKT signaling blockade, and Rational combination trials are ongoing to maximize clinical benefit with this therapeutic strategy.